期刊的影响因子--文章列表

期刊文章列表
Abi Maharjan^1,2,3，Hongyu Sun^1,4，Zeying Cao^1,3，Ke Li^3,5，Jinping Liu⁶，Jun Liu^1,7，Tiqiao Xiao⁵，Guanyun Peng⁵，Junqiu Ji⁷，Peter York¹，Balmukunda Regmi⁸，Xianzhen Yin^1,7，Jiwen Zhang^1,3,4，Li Wu^1,2（Center for Drug Delivery System，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；School of Pharmacy，Key Laboratory of Molecular Pharmacology and Drug Evaluation，Ministry of Education，Yantai University；University of Chinese Academy of Sciences；NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients，National Institutes for Food and Drug Control；Shanghai Synchrotron Radiation Facility/Zhangjiang Lab，Shanghai Advanced Research Institute，Chinese Academy of Sciences；Hefei Lifeon Medication Group；Center for MOST and Image Fusion Analysis，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；Maharajgung Medical Campus，Institute of Medicine，Tribhuvan University）.Redefinition to bilayer osmotic pump tablets as subterranean river system within mini-earth via three-dimensional structure mechanism[J].Acta Pharmaceutica Sinica B,2022,第5期 Elisa Rioja-Blanco^1,2，Irene Arroyo-Solera^1,2,3，Patricia álamo^1,2,3，Isolda Casanova^1,2,3，Alberto Gallardo^1,4，Ugutz Unzueta^1,2,3，Naroa Serna^3,5,6，Laura Sánchez-García^3,5,6，Miquel Quer^3,7，Antonio Villaverde^3,5,6，Esther Vázquez^3,5,6，Ramon Mangues^1,2,3，Lorena Alba-Castellón^1,2，Xavier León^3,7（Institut d'Investigació Biomèdica Sant Pau(IIB-Sant Pau) Institut de Recerca contra la Leucèmia Josep Carreras CIBER de Bioingeniería，Biomateriales y Nanomedicina(CIBER-BBN)；Department of Pathology，Hospital de la Santa Creu i Sant Pau；Institut de Biotecnologia i de Biomedicina，Universitat Autònoma de Barcelona；Departament de Genètica i de Microbiologia，Universitat Autònoma de Barcelona；Department of Otorhinolaryngology，Hospital de la Santa Creu i Sant Pau）.Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4⁺ head and neck squamous cell carcinoma tumors[J].Acta Pharmaceutica Sinica B,2022,第5期 Youbo Zhang^1,2，Tingting Yan²，Tianxia Wang^1,3，Xiaoyan Liu¹，Keisuke Hamada²，Dongxue Sun²，Yizheng Sun¹，Yanfang Yang¹，Jing Wang¹，Shogo Takahashi²，Qiong Wang²，Kristopher W.Krausz²，Changtao Jiang⁴，Cen Xie²，Xiuwei Yang¹，Frank J.Gonzalez²（State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines，School of Pharmaceutical Sciences，Peking University；Laboratory of Metabolism，Center for Cancer Research，National Cancer Institute，National Institutes of Health；School of Life Science and Engineering，Lanzhou University of Technology；Department of Physiology and Pathophysiology，School of Basic Medical Sciences，Peking University，the Key Laboratory of Molecular Cardiovascular Science，Ministry of Education）.Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity[J].Acta Pharmaceutica Sinica B,2022,第5期 Gan Wang¹，Min Zhang^1,2，Ping Meng¹，Chengbo Long^1,2，Xiaodong Luo³，Xingwei Yang³，Yunfei Wang^1,4，Zhiye Zhang¹，James Mwangi^1,2,5，Peter Muiruri Kamau^1,2,5，Zhi Daic¹，Zunfu Ke⁶，Yi Zhang⁷，Wenlin Chen⁸，Xudong Zhao¹，Fei Ge⁹，Qiumin Lv^1,5，Mingqiang Rong^1,5，Dongsheng Li¹，Yang Jin¹⁰，Xia Sheng¹¹，Ren Lai^1,4,5,12（Key Laboratory of Animal Models and Human Disease Mechanisms，Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province，KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases，National Resource Center for Non-Human Primates，Kunming Primate Research Center，and National Research Facility for Phenotypic & Genetic Analysis of Model Animals(Primate Facility)，Kunming Institute of Zoology；University of Chinese Academy of Sciences；State Key Laboratory of Phytochemistry and Plant Resources in West China，Kunming Institute of Botany，Chinese Academy of Sciences；Institutes for Drug Discovery and Development，Chinese Academy of Sciences；Sino-African Joint Research Center，Chinese Academy of Science；Department of Pathology，First Affiliated Hospital，Sun Yat-sen University；Department of Orthopaedic Surgery，First Affiliated Hospital of Zhengzhou University；Department of Breast Surgery，Third Affiliated Hospital of Kunming Medical University，Yunnan Cancer Center；Department of Breast Surgery，First Affiliated Hospital of Kunming Medical University；Department of Biosciences，University of Oslo；Key Laboratory of Environment and Health，Ministry of Education & Ministry of Environmental Protection，And State Key Laboratory of Environmental Health，School of Public Health，Tongji Medical College，Huazhong University of Science and Technology；Center for Biosafety Mega-Science，Chinese Academy of Sciences）.Anticarin-β shows a promising antiosteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis[J].Acta Pharmaceutica Sinica B,2022,第5期 Weimin Yu^1,2，Gang Xu^3,4，Hui Chen¹，Li Xiao¹，Gang Liu^1,5，Pingping Hu¹，Siqi Li¹，Vivi Kasim⁶，Chunyu Zeng⁷，Xiaoyong Tong¹（School of Pharmaceutical Sciences，Chongqing University；Institute of Health Biological Chemical Medication，Chongqing Institute of Green and Intelligent Technology，Chinese Academy of Sciences；Institute of Medicine and Equipment for High Altitude Region，College of High Altitude Military Medicine，Army Medical University(Third Military Medical University)；Key Laboratory of High Altitude Medicine，People's Liberation Army；Henan Key Laboratory of Medical Tissue Regeneration，College of Basic Medical Sciences，Xinxiang Medical University；Key Laboratory of Biorheological Science and Technology，Ministry of Education，College of Bioengineering，Chongqing University；Department of Cardiology，Daping Hospital，Army Medical University(Third Military Medical University)）.The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1α/XBP1s pathway[J].Acta Pharmaceutica Sinica B,2022,第5期 Editoral Office of Acta Pharmaceutica Sinica（Editoral Office of Acta Pharmaceutica Sinica）.Information for Authors[J].Acta Pharmaceutica Sinica B,2022,第5期 Pengcheng Wang^1,2,3，Guangyi Zeng^1,2,3，Yu Yan^1,3，Song-yang Zhang^1,3，Yongqiang Dong^1,3，Yangming Zhang^1,3，Xingzhong Zhang^1,3，Huiying Liu^1,3，Zhipeng Zhang⁴，Changtao Jiang^1,2,3，Yanli Pang⁵（Department of Physiology and Pathophysiology，School of Basic Medical Sciences，Peking University，Key Laboratory of Molecular Cardiovascular Science，Ministry of Education；Center of Basic Medical Research，Institute of Medical Innovation and Research，Peking University Third Hospital；Center for Obesity and Metabolic Disease Research，School of Basic Medical Sciences，Peking University；General Surgery Department，Peking University Third Hospital；Center for Reproductive Medicine，Department of Obstetrics and Gynecology，Peking University Third Hospital）.Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition of ceramide generation[J].Acta Pharmaceutica Sinica B,2022,第4期 Minyang Fu，Dandan Peng，Tianxia Lan，Yuquan Wei，Xiawei Wei（Laboratory of Aging Research and Cancer Drug Target，State Key Laboratory of Biotherapy，National Clinical Research Center for Geriatrics，West China Hospital，Sichuan University）.Multifunctional regulatory protein connective tissue growth factor（CTGF）：A potential therapeutic target for diverse diseases[J].Acta Pharmaceutica Sinica B,2022,第4期 Tiecheng Zhong，Wenxin Zhang，Hongjie Guo，Xiaohui Pan，Xi Chen，Qiaojun He，Bo Yang，Ling Ding（Zhejiang Province Key Laboratory of Anti-Cancer Drug Research，Institute of Pharmacology and Toxicology，College of Pharmaceutical Sciences，Zhejiang University）.The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies[J].Acta Pharmaceutica Sinica B,2022,第4期 Tengfei Xue¹，Juan Ji¹，Yuqin Sun¹，Xinxin Huang²，Zhenyu Cai¹，Jin Yang¹，Wei Guo¹，Ruobing Guo¹，Hong Cheng²，Xiulan Sun^1,3（Department of Pharmacology，Neuroprotective Drug Discovery Key Laboratory，Jiangsu Key Laboratory of Neurodegeneration，Nanjing Medical University；The First Affiliated Hospital of Nanjing Medical University；Nanjing University of Chinese Medicine，the Affiliated Hospital of Nanjing University of Chinese Medicine）.Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury[J].Acta Pharmaceutica Sinica B,2022,第4期 Hui Liu¹，Weimin Qiu¹，Tianyu Sun¹，Lei Wang¹，Chenxi Du¹，Yanyu Hu²，Wenyuan Liu^1,3，Feng Feng^4,2，Yao Chen⁵，Haopeng Sun^1,4（School of Pharmacy，China Pharmaceutical University；Department of Natural Medicinal Chemistry，China Pharmaceutical University；Department of Pharmaceutical Analysis，Key Laboratory of Drug Quality Control and Pharmacovigilance，China Pharmaceutical University；Jiangsu Drug Development Engineering Research Center for Central Degenerative Disease，Jiangsu Food and Pharmaceuticals Science College；School of Pharmacy，Nanjing University of Chinese Medicine）.Therapeutic strategies of glioblastoma（GBM）：The current advances in the molecular targets and bioactive small molecule compounds[J].Acta Pharmaceutica Sinica B,2022,第4期 Lingxin Hou¹，Ying Zhang¹，Han Ju¹，Srinivasulu Cherukupalli¹，Ruifang Jia¹，Jian Zhang²，Bing Huang³，Arianna Loregian⁴，Xinyong Liu^1,5，Peng Zhan^1,5（Department of Medicinal Chemistry，Key Laboratory of Chemical Biology(Ministry of Education)，School of Pharmaceutical Sciences，Cheeloo College of Medicine，Shandong University；Institute of Medical Sciences，The Second Hospital，Cheeloo College of Medicine，Shandong University；Institute of Poultry Science，Shandong Academy of Agricultural Sciences；Department of Molecular Medicine，University of Padova；China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province）.Contemporary medicinal chemistry strategies for the discovery and optimization of infiuenza inhibitors targeting vRNP constituent proteins[J].Acta Pharmaceutica Sinica B,2022,第4期 Songli Wang^1,2，Ruifeng Wang¹，Nana Meng¹，Linwei Lu³，Jun Wang¹，Jianfen Zhou¹，Jiasheng Lu¹，Qianzhu Xu¹，Cao Xie¹，Changyou Zhan^1,2，Yao Li⁴，Yang Yu⁴，Weiyue Lu^1,5,6，Min Liu¹（Department of Pharmaceutics，School of Pharmacy，Key Laboratory of Smart Drug Delivery(Ministry of Education and PLA)，Fudan University；Department of Pharmacology，School of Basic Medical Sciences，Fudan University；The Department of Integrative Medicine，Huashan Hospital，Fudan University and the Institutes of Integrative Medicine of Fudan University；The National Facility for Protein Science in Shanghai(NFPS)；State Key Laboratory of Medical Neurobiology and the Collaborative Innovation Center for Brain Science and Department of Pharmacology，School of Basic Medical Sciences，Fudan University；Minhang Branch，Zhongshan Hospital and Institute of Fudan-Minhang Academic Health System，Minhang Hospital，Fudan University）.Engineered platelets-based drug delivery platform for targeted thrombolysis[J].Acta Pharmaceutica Sinica B,2022,第4期 Mengqi Xu¹，Cong Mao²，Haoting Chen²，Lu Liu³，Yabin Wang¹，Abid Hussain³，Sulei Li¹，Xu Zhang⁴，Ruslan G.Tuguntaev²，Xing-Jie Liang³，Weisheng Guo²，Feng Cao¹（Department of Cardiology，National Clinical Research Center for Geriatric Diseases&Second Medical Center of Chinese PLA General Hospital；Department of Minimally Invasive Interventional Radiology，Key Laboratory of Molecular Target&Clinical Pharmacology，School of Pharmaceutical Sciences&the Second Affiliated Hospital，Guangzhou Medical University；Laboratory of Controllable Nanopharmaceuticals，Chinese Academy of Sciences(CAS)Center for Excellence in Nanoscience and CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety，National Center for Nanoscience and Technology；Department of Urology，Chinese PLA General Hospital）.Osteopontin targeted theranostic nanoprobes for laser-induced synergistic regression of vulnerable atherosclerotic plaques[J].Acta Pharmaceutica Sinica B,2022,第4期 Lei Wu¹，Lingling Wang¹，Xi Liu¹，Yuli Bai¹，Ruinan Wu¹，Xiang Li¹，Yutong Mao¹，Ling Zhang²，Yongxiang Zheng³，Tao Gong¹，Zhirong Zhang¹，Yuan Huang¹（Key Laboratory of Drug Targeting and Drug Delivery System，Ministry of Education，West China School of Pharmacy，Sichuan University；Sichuan University，College of Polymer Science and Engineering；Sichuan University West China School of Pharmacy）.Milk-derived exosomes exhibit versatile effects for improved oral drug delivery[J].Acta Pharmaceutica Sinica B,2022,第4期 Boyi Niu¹，Yixian Zhou¹，Kaixin Liao¹，Ting Wen¹，Sixian Lao¹，Guilan Quan²，Xin Pan¹，Chuanbin Wu^1,2（School of Pharmaceutical Sciences，Sun Yat-sen University；College of Pharmacy，Jinan University）.“Pincer movement”：Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles[J].Acta Pharmaceutica Sinica B,2022,第4期 Chuanbin Yang^1,2，Chengfu Su^1,3,4，Ashok Iyaswamy^1,3，Senthil Kumar Krishnamoorthi¹，Zhou Zhu^1,3，Sichang Yang¹，Benjamin Chunkit Tong^1,3，Jia Liu^1,3，Sravan G.Sreenivasmurthy^1,3，Xinjie Guan¹，Yuxuan Kan¹，Aston Jiaxi Wu¹，Alexis Shiying Huang¹，Jieqiong Tan⁵，Kingho Cheung^1,3，Juxian Song^1,6，Min Li^1,3（Mr.&Mrs.Ko Chi-Ming Centre for Parkinson's Disease Research，School of Chinese Medicine，Hong Kong Baptist University；Department of Geriatrics，Shenzhen People's Hospital(the Second Clinical Medical College，Jinan University，the First Affiliated Hospital，Southern University of Science and Technology)；Institute for Research and Continuing Education，Hong Kong Baptist University；College of Pharmacy，Henan University of Chinese Medicine；Center for Medical Genetics and Hunan Key Laboratory of Animal Model for Human Diseases，School of Life Sciences，Central South University；Medical College of Acupuncture-Moxibustion and Rehabilitation，Guangzhou University of Chinese Medicine）.Celastrol enhances transcription factor EB（TFEB）-mediated autophagy and mitigates Tau pathology：Implications for Alzheimer’s disease therapy[J].Acta Pharmaceutica Sinica B,2022,第4期 Minsong Guo¹，Fengdan Zhu¹，Wenqiao Qiu^1,2，Gan Qiao¹，Betty Yuen-Kwan Law³，Lu Yu¹，Jianming Wu¹，Yong Tang^1,3，Chonglin Yu¹，Dalian Qin¹，Xiaogang Zhou¹，Anguo Wu¹（Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation，Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica，School of Pharmacy，Education Ministry Key Laboratory of Medical Electrophysiology，Southwest Medical University；Department of Neurosurgery Sichuan Provincial People's Hospital，University of Electronic Science and Technology of China；State Key Laboratory of Quality Research in Chinese Medicine，Macau University of Science and Technology）.High-throughput screening for amyloid-β binding natural small-molecules based on the combinational use of biolayer interferometry and UHPLC-DAD-Q/TOF-MS/MS[J].Acta Pharmaceutica Sinica B,2022,第4期 Guangdi Li¹，Yali Wang¹，Erik De Clercq²（Hunan Provincial Key Laboratory of Clinical Epidemiology，Xiangya School of Public Health，Central South University；Rega Institute for Medical Research，Department of Microbiology，Immunology and Transplantation）.Approved HIV reverse transcriptase inhibitors in the past decade[J].Acta Pharmaceutica Sinica B,2022,第4期 Xuejing Shao¹，Yingqian Chen¹，Wei Wang¹，Wenxin Du¹，Xingya Zhang¹，Minyi Cai¹，Shaowei Bing¹，Ji Cao^1,2,3，Xiaojun Xu⁴，Bo Yang^1,3，Qiaojun He^1,2,3，Meidan Ying^1,4,2（Institute of Pharmacology and Toxicology，Zhejiang Province Key Laboratory of Anti-Cancer Drug Research，College of Pharmaceutical Sciences，Zhejiang University；Cancer Center，Zhejiang University；Innovation Institute for Artificial Intelligence in Medicine，Zhejiang University；Children's Hospital，Zhejiang University School of Medicine，National Clinical Research Center for Child Health）.Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells[J].Acta Pharmaceutica Sinica B,2022,第4期 Hong Wang¹，Qianqian Wang¹，Guodi Cai¹，Zhijian Duan²，Zoann Nugent³，Jie Huang⁴，Jianwei Zheng¹，Alexander D.Borowsky⁵，Jian Jian Li⁶，Peiqing Liu^1,7，Hsing-Jien Kung^2,8，Leigh Murphy³，Hong-Wu Chen^2,8，Junjian Wang^1,7（School of Pharmaceutical Sciences，Sun Yat-sen University；Department of Biochemistry and Molecular Medicine，University of California；Research Institute in Oncology and Hematology，University of Manitoba and Cancer Care Manitoba；Guangdong Lung Cancer Institute，Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer，Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences；Department of Pathology and Laboratory Medicine，University of California；Department of Radiation Oncology，University of California；National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation，Guangdong Provincial Key Laboratory of New Drug Design and Evaluation，Sun Yat-sen University；UC Davis Comprehensive Cancer Center，School of Medicine，University of California）.Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via NRF2 in cancer therapeutic resistance[J].Acta Pharmaceutica Sinica B,2022,第4期 Qi Wang^1,2，Bixi Tang^3,2,4，Dandan Sun⁵，Ying Dong^3,2，Yinchun Ji⁶，Huanyu Shi^1,2，Liwei Zhou^1,7，Yueyue Yang^1,2，Menglan Luo^1,8，Qian Tan³，Lin Chen¹，Yue Dong⁹，Cong Li³，Rongrong Xie³，Yi Zang^3,2,10，Jingkang Shen¹，Bing Xiong^1,2，Jia Li^3,2,5,10，Danqi Chen¹（Department of Medicinal Chemistry，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；Department of Pharmacology，School of Pharmacy，Fudan University；School of Chinese Materia Medica，Nanjing University of Chinese Medicine；Division of Anti-tumor Pharmacology，State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；Center for Supramolecular Chemistry and Catalysis and Department of Chemistry，College of Sciences，Shanghai University；Department of Chemistry，College of Sciences，Shanghai University；Department of Pulmonary and Critical Care Medicine，Shanghai Fifth People’s Hospital，Fudan University；School of Pharmaceutical Science and Technology，Hangzhou Institute for Advanced Study，UCAS）.Discovery of 4-cyclopropyl-3-（2-（（1-cyclopropyl-1H-pyrazol-4-yl） amino） quinazolin-6-yl）-N-（3-（trifiuoromethyl） phenyl） benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis[J].Acta Pharmaceutica Sinica B,2022,第4期 Lei Feng^1,2，Xiangge Tian²，Dahong Yao³，Zhenlong Yu²，Xiaokui Huo^1,2，Zhenhao Tian⁴，Jing Ning²，Jingnan Cui⁴，Tony D.James^5,6，Xiaochi Ma^1,2（Second Affiliated Hospital，Dalian Medical University；College of Pharmacy，the National&Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease，Dalian Medical University；School of Pharmaceutical Sciences，Shenzhen Technology University；State Key Laboratory of Fine Chemicals，Dalian University of Technology；Department of Chemistry，University of Bath；School of Chemistry and Chemical Engineering，Henan Normal University）.A practical strategy to develop isoform-selective near-infrared fiuorescent probes for human cytochrome P450 enzymes[J].Acta Pharmaceutica Sinica B,2022,第4期 Hsiang-i Tsai^1,2，Yanping Wu¹，Rui Huang³，Dandan Su¹，Yingyi Wu¹，Xiaoyan Liu¹，Linglu Wang¹，Zhanxue Xu¹，Yuxin Pang⁴，Chong Sun⁵，Chao He¹，Fan Shu¹，Haitao Zhu²，Dongqing Wang²，Fang Cheng¹，Laiqiang Huang⁶，Hongbo Chen¹（School of Pharmaceutical Sciences(Shenzhen)，Sun Yat-sen University；Department of Medical Imaging，the Affiliated Hospital of Jiangsu University；Department of Hematology，Zhujiang Hospital，Southern Medical University；School of Traditional Medicine Materials Resource，Guangdong Pharmaceutical University；Immune Regulation in Cancer，German Cancer Research Center；The Shenzhen Key Lab of Gene and Antibody Therapy，Center for Biotechnology&Biomedicine，Division of Life and Health Sciences，Graduate School at Shenzhen，Tsinghua University）.PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhidi Pan¹，Jie Chen¹，Xiaodong Xiao^2,3，Yueqing Xie²，Hua Jiang^2,3，Baohong Zhang¹，Huili Lu¹，Yunsheng Yuan¹，Lei Han³，Yuexian Zhou¹，Huifang Zong¹，Lei Wang¹，Rui Sun¹，Jianwei Zhu^1,2,3（Engineering Research Center of Cell&Therapeutic Antibody，MOE，School of Pharmacy，Shanghai Jiao Tong University；Jecho Laboratories，Inc.；Jecho Biopharmaceuticals Co.，Ltd.）.Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement[J].Acta Pharmaceutica Sinica B,2022,第4期 Xueqin He¹，Xiaorong Wang¹，Lianyi Yang¹，Zhihang Yang¹，Wenqi Yu¹，Yazhen Wang¹，Rui Liu¹，Meiwan Chen²，Huile Gao¹（Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province，Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology，West China School of Pharmacy，Sichuan University；State Key Laboratory of Quality Research in Chinese Medicine，Institute of Chinese Medical Sciences，University of Macau）.Intelligent lesion blood-brain barrier targeting nano-missiles for Alzheimer’s disease treatment by anti-neuroinfiammation and neuroprotection[J].Acta Pharmaceutica Sinica B,2022,第4期 Yongrong Yao，Huachao Chen，Ninghua Tan（State Key Laboratory of Natural Medicines，School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第4期 Shuai Guo，Kening Li，Yanwen Chen，Bin Li（State Key Laboratory of Natural Medicines and School of Traditional Chinese Pharmacy，China Pharmaceutical University）.Unraveling the drug distribution in brain enabled by MALDI MS imaging with laser-assisted chemical transfer[J].Acta Pharmaceutica Sinica B,2022,第4期 Yang He^1,2,3,4，Yuefei Fang^1,5，Meng Zhang^1,6，Yuge Zhao¹，Bin Tu^1,2，Mingjie Shi¹，Bahtiyor Muhitdinov^1,7，Akmal Asrorov^1,7，Qin Xu⁵，Yongzhuo Huang^1,2,3,8（State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；Zhongshan Institute for Drug Discovery，Chinese Academy of Sciences；Department of Pharmacy，the First Affiliated Hospital of Zhengzhou University；Artemisinin Research Center，Guangzhou University of Chinese Medicine；Women's Hospital，School of Medicine，Zhejiang University；Institute of Bioorganic Chemistry，Uzbekistan Academy of Sciences；National Medical Products Administration，Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients）.Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona[J].Acta Pharmaceutica Sinica B,2022,第4期首页上一页 5 6 7 8 9 下一页尾页共有12页，转到页

期刊文章列表